Investors and partnerships

Investors

InhaTarget Therapeutics is currently running its proof-of-concept validations and its business development activities through regional funds, but the company will open its capital to interested investors to finance its growth, such as towards Phase I/IIa clinical trial, POC of other products in the pipeline, and others.

This series A funding will be open in the first semester of 2019.

Are you convinced by the high potential of the project, the team and the technologies?

Share your interest with us.

Send an email to investors@inhatarget.com and we will keep you informed of any progress of the project’s progress in both technology evolution and capital structuring.

Pharma partners

InhaTarget Therapeutics is currently further developing its proprietary products before transferring the conduct of later clinical studies (Phase IIb, III), regulatory approvals and marketing and sales operations to a pharma partner.

Are you interested in feeding your pipeline with our innovative cancer treatment solutions?

Share your interest with us.

Send an email to bd@inhatarget.com and we will keep you informed of the project’s progress in both technology evolution and clinical validation.


InhaTarget Therapeutics also provides a complete set of expertise and equipment for the early-stage development of innovative products for inhalation, in collaboration with interested pharma partners.

Have you identified a market opportunity for innovative inhalation drugs and seek specific expertise and equipment for the early development of a drug?

Request a discussion on your project.

Send an email to collaborations@inhatarget.com and we will get back to you quickly to discuss your opportunity further.

Our business promises

Creation of a promising new market

With the development of InhaTarget proprietary products, we aim to connect the DPI market with the lung cancer immunotherapy and chemotherapy markets.

New competitive advantage over well-known anticancer drugs

By developing new innovative DPI formulations, our strategy allows new patent protection of anticancer compounds that have fallen in the public domain but are still widely used in lung cancer treatments.

Time and cost reduction in clinical trials

The formulated anticancer drugs are gold standards in the clinical practice. Lung cancer is considered as an unmet clinical need.  Innovative treatments could therefore benefit from an accelerated regulatory review or even from fast track status.

libero in et, vel, elit. velit,